94 results
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
for clinical trial development of KVA12123 as well as general corporate purposes, partially offset by $8.6 million net proceeds received from
8-K
EX-99.1
KA
Kineta Inc
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
offset by $5.5 million net proceeds received from the registered direct offering in April 2023 and $5.0 million in cash received from the Merck milestone
8-K
EX-99.1
s0x7osx
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
1urj0k00jy5e4zxja28
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
8-K
EX-99.1
v0lurp56
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.5
1tk6k4nr55cnsbd
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
r4cew03
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
zb8l on57
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
opd v1x6o7c9r
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
4n3l02xdcl
10 Nov 22
Prospectus supplement
4:21pm